Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors
暂无分享,去创建一个
E. Montserrat | C. Martínez | E Montserrat | A Urbano-Ispizua | Á. Urbano-Ispizua | E Carreras | C Martínez | P Marín | A Merino | M Rovira | M. Rovira | P. Marín | E. Carreras | A. Merino | Emili Montserrat | Montserrat Rovira | Enric Carreras | Pedro Marín | Carmen Martínez
[1] J. Briones,et al. Effects of G-CSF administration and peripheral blood progenitor cell collection in 20 healthy donors , 1996, Annals of Hematology.
[2] D. Stroncek,et al. Treatment of normal individuals with granulocyte‐colony‐stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells , 1996, Transfusion.
[3] B. Andersson,et al. Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. , 1996, Bone marrow transplantation.
[4] N. Schmitz,et al. G‐CSF‐mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft , 1994, British journal of haematology.
[5] A. Santoro,et al. Mobilization and collection of PBSC in healthy donors: comparison between two schemes of rhG‐CSF administration , 1996, European journal of haematology.
[6] A. Roberts,et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. , 1995, Blood.
[7] D. Linch,et al. Optimal timing for collection of PBPC after glycosylated G-CSF administration , 1998, Bone Marrow Transplantation.
[8] R. Champlin,et al. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. , 1996, Blood.
[9] R. Champlin,et al. Clinical toxicity and laboratory effects of granulocyte‐colony‐ stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures , 1996, Transfusion.
[10] C. Dunbar,et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies , 1996 .
[11] J. Goldman. Peripheral blood stem cells for allografting. , 1995, Blood.
[12] Giralt,et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. , 1995, Blood.
[13] J. Doroshow,et al. Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer. , 1997, Blood.
[14] T. Tötterman,et al. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. , 1996, Bone marrow transplantation.
[15] R Storb,et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. , 1993, Blood.
[16] L Davies,et al. Bone marrow transplant. , 1985, Nursing times.
[17] P. Anderlini,et al. Transient neutropenia in normal donors after G‐CSF mobilization and stem cell apheresis , 1996, British journal of haematology.
[18] G. Bernini,et al. G-CSF serum pharmacokinetics during peripheral blood progenitor cell mobilization: neutrophil count-adjusted dosage might potentially improve mobilization and be more cost-effective , 1998, Bone Marrow Transplantation.
[19] H. Goldschmidt,et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. , 1994, Blood.
[20] B. McAneny,et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim , 1998, British journal of haematology.
[21] F. Benvenuto,et al. Influence of marrow CFU-GM content on engraftment and survival after allogeneic bone marrow transplantation. , 1995, Bone marrow transplantation.
[22] N. Kröger,et al. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 × 5 μg/kg) compared to a single dose (1 × 10 μg/kg) , 1999, Bone Marrow Transplantation.
[23] R Storb,et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. , 1997, Blood.